dx 8951 has been researched along with Colorectal Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doi, T; Hirotani, K; Kagari, T; Koga, Y; Koganemaru, S; Kojima, T; Kuboki, Y; Maeda, N; Matsumura, Y; Yamauchi, M; Yasunaga, M | 1 |
| Saijo, N | 1 |
1 review(s) available for dx 8951 and Colorectal Cancer
| Article | Year |
|---|---|
Preclinical and clinical trials of topoisomerase inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors | 2000 |
1 other study(ies) available for dx 8951 and Colorectal Cancer
| Article | Year |
|---|---|
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Broadly Neutralizing Antibodies; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Immunoconjugates; Mice; Receptor, ErbB-3; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |